CXCL9 inhibits tumour growth and drives anti-PD-L1 therapy in ovarian cancer
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
CXCL9 inhibits tumour growth and drives anti-PD-L1 therapy in ovarian cancer
Authors
Keywords
-
Journal
BRITISH JOURNAL OF CANCER
Volume 126, Issue 10, Pages 1470-1480
Publisher
Springer Science and Business Media LLC
Online
2022-03-22
DOI
10.1038/s41416-022-01763-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- CXCL9 secreted by tumor-associated dendritic cells up-regulates PD-L1 expression in bladder cancer cells by activating the CXCR3 signaling
- (2021) Weigang Xiu et al. BMC IMMUNOLOGY
- Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition
- (2021) Kevin Litchfield et al. CELL
- Chemokines and the immune response to cancer
- (2021) Aleksandra J. Ozga et al. IMMUNITY
- Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39)
- (2021) Kathleen N. Moore et al. JOURNAL OF CLINICAL ONCOLOGY
- Identification of a Prognostic Signature for Ovarian Cancer Based on the Microenvironment Genes
- (2021) Xiao Huo et al. Frontiers in Genetics
- Immunology and Immune Checkpoint Inhibition in Ovarian Cancer – Current Aspects
- (2021) Holger Bronger GEBURTSHILFE UND FRAUENHEILKUNDE
- Both T cell priming in lymph node and CXCR3-dependent migration are the key events for predicting the response of atezolizumab
- (2021) Toshiki Iwai et al. Scientific Reports
- Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial
- (2020) Richard T. Penson et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic gene expression signature for high-grade serous ovarian cancer
- (2020) J. Millstein et al. ANNALS OF ONCOLOGY
- Combination of PARP inhibitor olaparib, and PD-L1 inhibitor durvalumab, in recurrent ovarian cancer: a proof-of-concept phase 2 study
- (2020) Erika J Lampert et al. CLINICAL CANCER RESEARCH
- Final results from the KEYNOTE-100 trial of pembrolizumab in patients with advanced recurrent ovarian cancer.
- (2020) Ursula A. Matulonis et al. JOURNAL OF CLINICAL ONCOLOGY
- The forefront of ovarian cancer therapy: update on PARP inhibitors
- (2020) M.R. Mirza et al. ANNALS OF ONCOLOGY
- Baseline Frequency of Inflammatory Cxcl9-Expressing Tumor-Associated Macrophages Predicts Response to Avelumab Treatment
- (2020) Yan Qu et al. Cell Reports
- 814MO Phase II study of olaparib (O) plus durvalumab (D) and bevacizumab (B) (MEDIOLA): Initial results in patients (pts) with non-germline BRCA-mutated (non-gBRCAm) platinum sensitive relapsed (PSR) ovarian cancer (OC)
- (2020) Y. Drew et al. ANNALS OF ONCOLOGY
- Emerging role of immune checkpoint inhibitors in the treatment of ovarian cancer
- (2020) Domenica Lorusso et al. EXPERT OPINION ON EMERGING DRUGS
- A bilateral tumor model identifies transcriptional programs associated with patient response to immune checkpoint blockade
- (2020) Ivy X. Chen et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Development and Validation of a Novel 11-Gene Prognostic Model for Serous Ovarian Carcinomas Based on Lipid Metabolism Expression Profile
- (2020) Mingjun Zheng et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer
- (2019) Mary L. Disis et al. JAMA Oncology
- Antitumor Activity and Safety of Pembrolizumab in Patients with Advanced Recurrent Ovarian Cancer: Results from the Phase 2 KEYNOTE-100 Study
- (2019) U A Matulonis et al. ANNALS OF ONCOLOGY
- Intratumoral Activity of the CXCR3 Chemokine System Is Required for the Efficacy of Anti-PD-1 Therapy
- (2019) Melvyn T. Chow et al. IMMUNITY
- PARP Inhibitor Efficacy Depends on CD8+ T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer
- (2019) Constantia Pantelidou et al. Cancer Discovery
- Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors
- (2019) Denarda Dangaj et al. CANCER CELL
- Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma
- (2019) Panagiotis A. Konstantinopoulos et al. JAMA Oncology
- Safety, clinical activity and biomarker assessments of atezolizumab from a Phase I study in advanced/recurrent ovarian and uterine cancers
- (2019) Joyce F. Liu et al. GYNECOLOGIC ONCOLOGY
- 1190PDPhase II study of olaparib + durvalumab (MEDIOLA): Updated results in germline BRCA-mutated platinum-sensitive relapsed (PSR) ovarian cancer (OC)
- (2019) Y Drew et al. ANNALS OF ONCOLOGY
- Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade
- (2019) Imran G. House et al. CLINICAL CANCER RESEARCH
- CXCL9/10/11, a regulator of PD-L1 expression in gastric cancer
- (2018) Chenlu Zhang et al. BMC CANCER
- Interferon Gamma Messenger RNA Signature in Tumor Biopsies Predicts Outcomes in Patients with Non–Small Cell Lung Carcinoma or Urothelial Cancer Treated with Durvalumab
- (2018) Brandon W. Higgs et al. CLINICAL CANCER RESEARCH
- BRCA1/2 and TP53 mutation status associates with PD-1 and PD-L1 expression in ovarian cancer
- (2018) Verena Wieser et al. Oncotarget
- PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness
- (2018) Jianfeng Shen et al. CANCER RESEARCH
- PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer
- (2018) Liya Ding et al. Cell Reports
- CXCR3 mediates ascites-directed tumor cell migration and predicts poor outcome in ovarian cancer patients
- (2017) C Windmüller et al. Oncogenesis
- QuPath: Open source software for digital pathology image analysis
- (2017) Peter Bankhead et al. Scientific Reports
- CXCL9 and CXCL10 predict survival and are regulated by cyclooxygenase inhibition in advanced serous ovarian cancer
- (2016) Holger Bronger et al. BRITISH JOURNAL OF CANCER
- CRISPR/Cas9-Mediated Trp53 and Brca2 Knockout to Generate Improved Murine Models of Ovarian High-Grade Serous Carcinoma
- (2016) J. Walton et al. CANCER RESEARCH
- Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer
- (2016) Kyle C. Strickland et al. Oncotarget
- Safety and Antitumor Activity of Anti–PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer
- (2015) Junzo Hamanishi et al. JOURNAL OF CLINICAL ONCOLOGY
- Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy
- (2015) Dongjun Peng et al. NATURE
- Evaluating cell lines as tumour models by comparison of genomic profiles
- (2013) Silvia Domcke et al. Nature Communications
- Integrated genomic analyses of ovarian carcinoma
- (2011) D. Bell et al. NATURE
- Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome
- (2008) R. W. Tothill et al. CLINICAL CANCER RESEARCH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search